These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 34254291)

  • 1. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.
    Català A; Muñoz-Santos C; Galván-Casas C; Roncero Riesco M; Revilla Nebreda D; Solá-Truyols A; Giavedoni P; Llamas-Velasco M; González-Cruz C; Cubiró X; Ruíz-Villaverde R; Gómez-Armayones S; Gil Mateo MP; Pesqué D; Marcantonio O; Fernández-Nieto D; Romaní J; Iglesias Pena N; Carnero Gonzalez L; Tercedor-Sanchez J; Carretero G; Masat-Ticó T; Rodríguez-Jiménez P; Gimenez-Arnau AM; Utrera-Busquets M; Vargas Laguna E; Angulo Menéndez AG; San Juan Lasser E; Iglesias-Sancho M; Alonso Naranjo L; Hiltun I; Cutillas Marco E; Polimon Olabarrieta I; Marinero Escobedo S; García-Navarro X; Calderón Gutiérrez MJ; Baeza-Hernández G; Bou Camps L; Toledo-Pastrana T; Guilabert A
    Br J Dermatol; 2022 Jan; 186(1):142-152. PubMed ID: 34254291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study.
    Cebeci Kahraman F; Savaş Erdoğan S; Aktaş ND; Albayrak H; Türkmen D; Borlu M; Arıca DA; Demirbaş A; Akbayrak A; Polat Ekinci A; Gökçek GE; Çelik HA; Taşolar MK; An İ; Temiz SA; Hazinedar E; Ayhan E; Hızlı P; Solak EÖ; Kılıç A; Yılmaz E
    J Cosmet Dermatol; 2022 Sep; 21(9):3692-3703. PubMed ID: 35780311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV-19 corona virus vaccine (recombinant).
    Sandhu S; Bhatnagar A; Kumar H; Dixit PK; Paliwal G; Suhag DK; Patil C; Mitra D
    Dermatol Ther; 2021 Nov; 34(6):e15141. PubMed ID: 34546608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.
    McMahon DE; Amerson E; Rosenbach M; Lipoff JB; Moustafa D; Tyagi A; Desai SR; French LE; Lim HW; Thiers BH; Hruza GJ; Blumenthal KG; Fox LP; Freeman EE
    J Am Acad Dermatol; 2021 Jul; 85(1):46-55. PubMed ID: 33838206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis.
    Singh RB; Parmar UPS; Ichhpujani P; Jeng BH; Jhanji V
    Cornea; 2023 Jun; 42(6):731-738. PubMed ID: 36706232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency.
    Krzywicka K; Heldner MR; Sánchez van Kammen M; van Haaps T; Hiltunen S; Silvis SM; Levi M; Kremer Hovinga JA; Jood K; Lindgren E; Tatlisumak T; Putaala J; Aguiar de Sousa D; Middeldorp S; Arnold M; Coutinho JM; Ferro JM
    Eur J Neurol; 2021 Nov; 28(11):3656-3662. PubMed ID: 34293217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
    Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Pályi B; Formanek-Balku E; Molnár GA; Herczeg R; Gyenesei A; Miseta A; Kollár L; Wittmann I; Müller C; Kásler M
    Clin Microbiol Infect; 2022 Mar; 28(3):398-404. PubMed ID: 34838783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant).
    Job AM; Sudhamani B; Mohan M; Mohanasundaram SN
    Indian J Public Health; 2022; 66(1):83-85. PubMed ID: 35381724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2.
    Sprute R; Schumacher S; Pauls M; Pauls W; Cornely OA
    Drugs R D; 2021 Dec; 21(4):371-374. PubMed ID: 34351606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between SARS-CoV-2 vaccination and healthcare contacts for menstrual disturbance and bleeding in women before and after menopause: nationwide, register based cohort study.
    Ljung R; Xu Y; Sundström A; Leach S; Hallberg E; Bygdell M; Larsson M; Arthurson V; Gisslén M; Gedeborg R; Nyberg F
    BMJ; 2023 May; 381():e074778. PubMed ID: 37137493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Milk Antibody Response After Combining Two Different COVID-19 Vaccines: Mix-and-Match.
    Mulleners SJ; Juncker HG; van Gils MJ; van Goudoever JB; van Keulen BJ
    J Hum Lact; 2022 Aug; 38(3):401-406. PubMed ID: 35726498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database.
    Falotico JM; Desai AD; Shah A; Ricardo JW; Lipner SR
    Am J Clin Dermatol; 2022 Sep; 23(5):729-737. PubMed ID: 35931925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
    Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
    Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study.
    Lee DS; Kim JW; Lee KL; Jung YJ; Kang HW
    Int J Infect Dis; 2022 May; 118():173-182. PubMed ID: 35276381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.